Our Team

SCIENTIFIC ADVISOR

Dr. John H. Krystal, serves as the Robert L. McNeil, Jr. Professor of Translational Research and Chair of the Department of Psychiatry at Yale University, while also being the Chief of Psychiatry at Yale-New Haven Hospital. With a BA from the University of Chicago and an MD from Yale, Dr. Krystal is renowned for his work in psychiatric disorders including PTSD and depression, using neuroscience and pharmacology to forge new treatment paths. He has authored over 500 publications and has been recognized with several awards for his dedication to translational research, bridging the gap between research and clinical practice to enhance patient outcomes. His efforts are underlined by a commitment to evidence-based psychiatry and involvement in several pharma SABs.

SCIENTIFIC ADVISOR

Dr. Gerard Sanacora is a prominent psychiatrist and a professor at Yale University, holding the title of George D. Gross and Esther S. Gross Professor of Psychiatry. He completed an NIH sponsored Medical Scientist Training Program at the State University New York at Stony Brook, earning his Ph.D. in Physiology and Biophysics in 1992 and his M.D. degree in 1994. His notable career is marked by extensive research in the field of depression, where he delves deep into understanding the underlying neurobiological mechanisms of the disease. Serving as the Director of the Yale Depression Research Program, his research extensively involves exploring innovative treatment approaches for mood disorders, particularly focusing on the role of glutamate.

MEDICAL ADVISOR

Dr. Andrew J. Gerber is President and Medical Director of Silver Hill Hospital in New Canaan, Connecticut. He completed his medical and psychiatric training at Harvard Medical School, Cambridge Hospital and Weill Cornell and Columbia Medical Schools. Dr. Gerber completed a PhD in Psychology at University College London. Prior to joining Silver Hill, Dr. Gerber was Medical Director and CEO of the Austen Riggs Center in Stockbridge, Massachusetts and Director of the MRI Research Program at the New York State Psychiatric Institute. Dr. Gerber serves as Associate Clinical Professor in the Division of Child and Adolescent Psychiatry at Columbia University Medical Center and as Associate Clinical Professor at the Child Study Center, Yale University. Dr. Gerber’ s interests include developmental psychopathology, attachment, and functional neuroimaging of psychotherapeutic processes, including social cognition.

ADVISOR

Dr. Justin Baker is a trailblazer in digital mental health, merging consumer technology, neuroscience, and clinical psychiatry to address the critical shortfall in quality mental health services. With vast experience advising leading mental health technology firms such as Ginger and Pear Therapeutics, as well as spearheading initiatives like the Baseline Mood Study at Google / Verily Life Sciences, Justin's impact is profound. His recent roles as Chief Medical Officer and Chief Scientific Officer at Mindstrong, and as founder of the Institute for Technology in Psychiatry at McLean Hospital, underscore his commitment to innovative research and ethical exploration in the field. Justin's multidisciplinary approach, blending biological and digital methodologies, facilitates in-depth longitudinal studies crucial for understanding complex mental illnesses. As a board-certified psychiatrist at Harvard Medical School, he champions the integration of scientific breakthroughs into practical clinical solutions, driving transformative change in mental healthcare.

CLINICAL ADVISOR

Dr. Lois Choi-Kain is a pioneer and internationally renowned expert in the treatment of personality disorders. She holds a Bachelor’s and Master’s degree from Harvard University, where she studied social and political theory, human development, and history of psychiatry. She received her M.D. from Thomas Jefferson University, and completed her residency training at Harvard Medical School. In 2009, Dr. Choi-Kain developed the Gunderson Residence, a specialized residential program for adult women with severe personality disorders. In 2013, she founded the BPD Training Institute, a major center for proliferating awareness of and trainings for evidence-based care for severe personality disorders. Dr. Choi-Kain has also developed training clinics in McLean’s Adult Outpatient Services for treatment approaches such as MBT and DBT-PTSD. She transformed the BPD Training Institute when she launched a formal research laboratory into its current form as Gunderson Personality Disorders Institute, which provides training and supervision for numerous proven treatments and conduct research on personality disorders and novel interventions built for them to increase access to care.

BOARD MEMBER

Isaac Barchas is CEO and co-founder of Research Bridge Partners (RBP), a biotechnology accelerator. Barchas built RBP’s team and strategy and co-manages new venture creation and investment activity. At RBP, Barchas has served as founding board member of Tetricus Labs, Eradivir, and MorphImmune and as lead turnaround board member of Novosteo. Barchas is also a managing director of RBP-Catalyst Fund I and Arsenal Bridge Ventures II. Prior to founding RBP, Barchas led the Austin Technology Incubator, helping raise ~$1B in investor capital. Barchas came to ATI from McKinsey & Co. Barchas served on the leadership teams of McKinsey’s North American Payor/Provider and global Organization practices. Barchas received his AB from Stanford University and his Master’s and JD degrees from The University of Chicago.